Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Catalyst Pharmaceuticals (CPRX) Leases (2019 - 2026)

Catalyst Pharmaceuticals filings provide 8 years of Leases readings, the most recent being $1.9 million for Q1 2026.

  • On a quarterly basis, Leases fell 13.9% to $1.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.9 million, a 13.9% decrease, with the full-year FY2025 number at $1.9 million, down 13.23% from a year prior.
  • Leases hit $1.9 million in Q1 2026 for Catalyst Pharmaceuticals, down from $1.9 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $3.0 million in Q1 2022 to a low of $1.9 million in Q1 2026.
  • Median Leases over the past 5 years was $2.4 million (2024), compared with a mean of $2.4 million.
  • Biggest five-year swings in Leases: decreased 8.19% in 2022 and later decreased 13.9% in 2026.
  • Catalyst Pharmaceuticals' Leases stood at $2.8 million in 2022, then dropped by 9.46% to $2.5 million in 2023, then dropped by 11.08% to $2.2 million in 2024, then dropped by 13.23% to $1.9 million in 2025, then decreased by 3.98% to $1.9 million in 2026.
  • The last three reported values for Leases were $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025) per Business Quant data.